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The XXV Congress of the International Society on Thrombosis and 
Haemostasis (ISTH 2015 Congress) marked a major milestone in the 
management of patients with hemophilia, with the announcement 
of key clinical trial results from studies of three innovative new 
recombinant coagulation factors that have been developed to ease 
the burden of hemophilia care. Phase III studies of CSL Behring’s 
recombinant single-chain factor VIII (rVIII-SingleChain) and re-
combinant fusion protein linking recombinant coagulation factor 
IX with recombinant albumin (rIX-FP) have now been completed, 
and the results were reported for the first time at this congress. 
Attendees also heard news of the company’s novel recombinant 
fusion protein linking recombinant coagulation factor VIIa with 
recombinant albumin (rVIIa-FP), which has now progressed into 
clinical trials in patients with hemophilia A or B with inhibitors, and 
in patients with congenital factor VII deficiency.
To celebrate these milestones and recognize the vital contri-
bution made by the patients, clinicians, researchers, and other 
scientists involved in the studies around the world, CSL Behring 
hosted a scientific symposium at the ISTH 2015 Congress entitled 
“Pioneering Therapeutic Proteins in Hemophilia Care Through Inno va-
tive Technologies”. The articles in this supplement summarize the 
presentations from that symposium.
In the first paper, Professor Ingrid Pabinger-Fasching from the 
Medical University of Vienna in Austria tells the story of the unique 
rVIII-SingleChain for the treatment of hemophilia A. The molecule 
has been engineered to offer increased stability and a higher binding 
affinity to von Willebrand factor than current treatments, with 
an improved pharmacokinetic and pharmacodynamic profile in 
preclinical and clinical studies. In her paper, Prof. Pabinger-Fasching 
presents an overview of the latest results from a recently completed 
phase I/III study with rVIII-SingleChain in previously treated 
patients with hemophilia A, confirming that this molecule has good 
hemostatic efficacy and is well tolerated.
In the second paper, Dr. Elena Santagostino from Maggiore 
Hospital and the University of Milan, Italy, provides an update on 
the results from the PROLONG-9FP clinical development program 
for rIX-FP, which has generated considerable interest amongst 
the hemophilia community. Dr. Santagostino describes the highly 
anticipated results from two phase III studies of rIX-FP in previously 
treated adults, adolescents, and pediatrics with severe hemophilia 
B, which were presented for the first time at the ISTH 2015 Congress. 
These studies have confirmed that rIX-FP is a truly remarkable 
new treatment that will transform the lives of many patients with 
hemophilia B, extending the dosing interval for FIX prophylaxis from 
every 3 or 4 days to every 7 or 14 days.
In the final paper, Prof. Claude Négrier from the Louis Pradel 
University Hospital in Lyon, France, contributes a paper describing 
the latest findings from the PROLONG-7FP program, which is the 
clinical development program for CSL Behring’s novel fusion protein, 
rVIIa-FP. Initial results from a phase I study of rVIIa-FP in healthy 
volunteers suggests that this new molecule has a markedly extended 
half-life compared with the currently available recombinant factor 
VIIa, offering the potential for more sustained hemostasis and 
more manageable prophylaxis schedules. Studies in patients with 
hemophilia A or B and inhibitors, and in those with congenital FVII 
deficiency, are now underway.
The papers in this supplement bring together all the latest 
findings from the comprehensive clinical development programs 
underway for CSL Behring’s most advanced recombinant coagulation 
factors. CSL Behring has always been considered to be a pioneer 
in the plasma therapeutics industry, and we are delighted that 
the company has committed to developing these – and other – 
innovative new recombinant technologies from which our patients 
may soon be able to benefit.
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